A Double‐Blind, Randomized, Placebo and Active‐Controlled Study of Nebicapone for the Treatment of Motor Fluctuations in Parkinson's Disease
- 9 November 2010
- journal article
- research article
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 16 (6) , 337-347
Abstract
To determine the efficacy, safety and tolerability of nebicapone, a new catechol-O-methyltransferase inhibitor for the treatment of motor fluctuations in Parkinson's disease (PD), we conducted a multicenter, randomized, 8-week double-blind, placebo- and active-controlled, parallel-group study comparing nebicapone 50 mg, 100 mg, or 150 mg, entacapone 200 mg (active control) or placebo administered concomitantly with levodopa/carbidopa or levodopa/benserazide. Two hundred and fifty-two PD patients with motor fluctuations treated with levodopa/carbidopa or levodopa/benserazide (4-8 daily doses) were enrolled and 250 patients were eligible for intention-to-treat (ITT) analysis on the basis of having at least one efficacy assessment. The primary endpoint was 8-week change from baseline in absolute "Off" time duration noted in self-scoring diaries. At 8 weeks of treatment the mean daily "Off" time decreased significantly compared to placebo for nebicapone 150 mg (-106 min; 95%CI: -192; -21) and entacapone 200 mg (-81 min; 95%CI: -142; -19). The decrease in "Off" time with nebicapone 50 mg or 100 mg did not reach statistical significance. Treatment-emergent adverse events were reported by 32% to 49% of patients in any treatment group, with no observed dose relationship in the nebicapone groups. Clinically relevant elevations in aspartate transaminase (AST) and/or alanine transaminase (ALT) were observed in 4 of 46 patients with the nebicapone 150 mg dose. The results of this study show that nebicapone 150 mg is efficacious for the treatment of motor fluctuations in PD patients. However, the risk of increasing liver transaminases and its clinically relevance deserves further evaluation.Keywords
This publication has 26 references indexed in Scilit:
- Pharmacokinetic—pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: A single-center, phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjectsClinical Therapeutics, 2009
- Effects of Nebicapone on Levodopa Pharmacokinetics, Catechol-O-methyltransferase Activity, and Motor Fluctuations in Patients with Parkinson DiseaseClinical Neuropharmacology, 2008
- Catechol‐O‐methyltransferase and Its Inhibitors in Parkinson's DiseaseCNS Drug Reviews, 2007
- TolcaponeClinical Neuropharmacology, 2007
- Treatment of End-of-Dose Wearing-Off in Parkinson’s Disease: Stalevo® (Levodopa/Carbidopa/Entacapone) and Levodopa/DDCI Given in Combination with Comtess®/Comtan® (Entacapone) Provide Equivalent Improvements in Symptom Control Superior to That of Traditional Levodopa/DDCI TreatmentEuropean Neurology, 2005
- Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestationsMovement Disorders, 2005
- Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004Movement Disorders, 2005
- Pharmacokinetic–Pharmacodynamic Interaction Between BIA 3-202, a Novel COMT Inhibitor, and Levodopa/CarbidopaClinical Neuropharmacology, 2004
- Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patientsJournal of Neurology, Neurosurgery & Psychiatry, 1997
- Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.Journal of Neurology, Neurosurgery & Psychiatry, 1992